📋 Key Information Summary
- MGUS is the most common plasma cell disorder, present in approximately 3–5% of adults aged ≥50 years; it is an incidental finding in the vast majority of cases and is not in itself malignant.
- Diagnostic criteria (IMWG): serum M-protein <30 g/L, bone marrow clonal plasma cells <10%, and absence of myeloma-defining events (hypercalcaemia, renal impairment, anaemia, bone lesions — CRAB criteria).
- MGUS is typically detected incidentally on serum protein electrophoresis (SPEP) or immunofixation performed for another indication (e.g. unexplained anaemia, neuropathy, recurrent infections).
- Baseline workup is mandatory and must include: M-protein quantification, immunoglobulin subtype (IgG / IgA / IgM), serum free light chain (FLC) ratio, full blood count, serum calcium, creatinine/eGFR, and skeletal imaging.
- Risk stratification uses the Mayo Clinic model: three independent risk factors — M-protein ≥15 g/L, non-IgG isotype, and abnormal FLC ratio (<0.26 or >1.65). Each factor increases the annual risk of progression (~1% per year overall).
- Low-risk MGUS (0 risk factors): approximately 5% cumulative risk of progression at 20 years — the majority will never progress.
- High-risk MGUS (3 risk factors): approximately 58% cumulative risk of progression at 20 years — closer monitoring is essential.
- IgM MGUS is biologically distinct and progresses predominantly to Waldenström macroglobulinaemia (WM) rather than multiple myeloma; it requires a separate diagnostic and monitoring pathway.
- Red flags demanding urgent haematology referral: new or worsening anaemia, hypercalcaemia, renal dysfunction, bone pain/lytic lesions, unexplained weight loss, night sweats, or B-symptoms.
- No pharmacological treatment is indicated for MGUS. Management is watchful monitoring with periodic laboratory reassessment.
- Low-risk monitoring: SPEP and FLC at 6 months, then annually if stable; may extend to every 2–3 years after 5+ years of stability. High-risk or IgM MGUS: haematology-led monitoring every 3–6 months.
- Patient counselling is critical: educate patients on symptoms of progression (bone pain, fatigue, recurrent infections, weight loss, bleeding) and provide written information from Leukaemia Foundation or Blood Cancer Australia.
- Aboriginal and Torres Strait Islander Australians may face barriers to haematology access and culturally safe communication; use remote monitoring pathways and culturally appropriate resources where available.
- Referral to haematology is recommended at initial diagnosis for risk assessment; low-risk cases may subsequently be monitored in primary care with haematology guidance.
Introduction & Australian Epidemiology
Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma cell disorder characterised by the presence of a monoclonal protein (M-protein) in the serum or urine, without evidence of end-organ damage or progression to a lymphoproliferative malignancy. It is the most common clonal plasma cell disorder and is found incidentally in the vast majority of cases.
MGUS is defined by the International Myeloma Working Group (IMWG) criteria:
- Serum M-protein <30 g/L
- Bone marrow clonal plasma cells <10%
- Absence of end-organ damage attributable to the plasma cell clone (no CRAB features: hypercalcaemia, renal impairment, anaemia, bone lesions)
- Absence of myeloma-defining events including ≥60% bone marrow plasma cells, involved/uninvolved FLC ratio ≥100 (with involved FLC ≥100 mg/L), or >1 focal lesion on MRI ≥5 mm
Australian Epidemiology
MGUS prevalence in Australia mirrors international data and increases substantially with age:
| Age Group | Estimated Prevalence | Notes |
|---|---|---|
| Under 40 years | <0.5% | Exceedingly rare; consider alternative diagnoses |
| 50–59 years | ~2.5–3% | Prevalence increases with each decade |
| 60–69 years | ~4–5% | Most common age group for incidental detection |
| 70–79 years | ~6–7% | Competing comorbidities often dominate management |
| ≥80 years | ~8–10% | Progression risk may be less clinically relevant |
The overall rate of progression from MGUS to multiple myeloma, Waldenström macroglobulinaemia (WM), or other lymphoproliferative malignancies is approximately 1% per year, though this varies substantially by risk category. In Australia, multiple myeloma accounts for approximately 2,200 new diagnoses annually (AIHW Cancer Data in Australia, 2024), and the majority of these cases arise from a preceding MGUS phase, often undetected.
MGUS is slightly more common in males and in people of African descent. In the Australian context, Aboriginal and Torres Strait Islander Australians may have different prevalence patterns and face barriers to timely detection and monitoring (see ATSI section).
MGUS is not a benign diagnosis to be ignored. While most patients will never progress, the ~1% per year cumulative risk means that lifelong awareness and periodic monitoring are essential. Patients must be counselled on symptoms of progression and ensured of ongoing follow-up.
Detection of MGUS
MGUS is almost always discovered incidentally. The clinician should maintain a high index of suspicion when serum protein electrophoresis (SPEP) or immunofixation reveals a monoclonal protein in the absence of obvious myeloma-defining features.
Common Clinical Scenarios Leading to Detection
1
Unexplained Anaemia
Microcytic or normocytic anaemia in an older adult investigated with iron studies, B12/folate, reticulocyte count — SPEP performed as part of the workup reveals a paraprotein.
2
Recurrent Infections
Recurrent sinopulmonary or skin infections in an older patient; immunoglobulin levels ordered as part of immune deficiency screening reveal a monoclonal protein with suppressed normal immunoglobulins.
3
Peripheral Neuropathy
Unexplained sensory or sensorimotor neuropathy; SPEP/immunofixation and anti-MAG antibodies ordered in the evaluation of chronic demyelinating neuropathy reveal an IgM paraprotein.
4
Elevated ESR or Total Protein
Incidentally elevated erythrocyte sedimentation rate (ESR), total serum protein, or a "rouleaux formation" on a blood film leads to SPEP.
5
Bone Pain or Osteoporosis
Unexplained bone pain or pathological fracture in an older adult; skeletal imaging and laboratory workup including SPEP reveal a paraprotein. Must exclude myeloma bone disease.
Initial Investigations at Detection
Once an M-protein is identified, the following baseline investigations should be performed promptly. These are all available on the Medicare Benefits Schedule (MBS) and can be ordered by a general practitioner:
Essential
Serum protein electrophoresis (SPEP) with immunofixation
Quantifies M-protein and determines heavy-chain isotype (IgG, IgA, IgM, IgD, IgE). Immunofixation confirms monoclonality and identifies light-chain type (κ or λ). Available on MBS.
Essential
Serum free light chain assay (FLC — κ and λ with ratio)
Critical for risk stratification. Abnormal FLC ratio (<0.26 or >1.65) is an independent risk factor for progression. Available on MBS; may require authority in some settings.
Essential
Full blood count (FBC) with differential and blood film
Assess for anaemia, thrombocytopenia, leucopenia, and rouleaux formation. Available on MBS.
Essential
Serum calcium (corrected for albumin)
Hypercalcaemia (>2.60 mmol/L corrected) is a CRAB criterion and indicates possible progression to myeloma. Available on MBS.
Essential
Serum creatinine with eGFR
Renal impairment (eGFR <60 mL/min/1.73 m² due to paraprotein) is a CRAB criterion. Available on MBS.
Available
24-hour urine for Bence Jones protein (urine protein electrophoresis and immunofixation)
Detects urinary light-chain excretion. Important for light-chain MGUS and AL amyloidosis screening. Available on MBS.
Available
Quantitative immunoglobulins (IgG, IgA, IgM)
Assesses suppression of uninvolved immunoglobulins (immune paresis). Available on MBS.
Available
Skeletal survey (plain X-rays) or whole-body low-dose CT (WBLD-CT)
Assess for lytic bone lesions. WBLD-CT is more sensitive than plain X-rays and is increasingly preferred (myeloma MRI/WBLD-CT recommended by IMWG 2019). Requires radiology referral.
Referral
Bone marrow aspirate and trephine biopsy
Not routinely required for MGUS diagnosis unless there is clinical suspicion of progression. Haematologist-directed investigation. Required to distinguish MGUS from smouldering myeloma.
Specialist
Whole-body MRI or PET-CT
For equivocal cases or when progression is suspected but WBLD-CT is negative. Specialist-ordered investigation.
Key point: An M-protein detected on SPEP must always be confirmed with immunofixation. A monoclonal protein on immunofixation is required to establish the diagnosis of MGUS. Transient or low-level M-proteins may be seen in infection or autoimmune conditions and may not represent true MGUS — repeat testing after 2–4 weeks may be warranted.
Baseline Risk Stratification
Once MGUS is confirmed, risk stratification is essential to determine the intensity and frequency of ongoing monitoring. The most widely used model is the Mayo Clinic risk-stratification model, which identifies three independent predictors of progression to multiple myeloma or related malignancy.
Mayo Clinic Risk-Stratification Model
Three independent risk factors are assessed at baseline. Each factor confers an approximately equivalent increase in progression risk:
| Risk Factor | Threshold | Rationale |
|---|---|---|
| M-protein level | ≥15 g/L | Higher tumour burden correlates with greater progression risk |
| Non-IgG isotype | IgA or IgM | IgA and IgM MGUS have higher progression rates than IgG MGUS |
| Abnormal FLC ratio | <0.26 or >1.65 | Reflects an increased burden of clonal light-chain production |
Risk Groups and Progression Rates
Low Risk
0 Risk Factors
5% cumulative risk of progression at 20 years (~0.3% per year). The majority of MGUS patients fall into this category.
Monitoring: SPEP every 6–12 months initially, then every 2–3 years if stable
Low-Intermediate
1 Risk Factor
21% cumulative risk of progression at 20 years (~1% per year). Requires closer attention to monitoring adherence.
Monitoring: SPEP and FLC every 6–12 months; haematology review at initial diagnosis
High-Intermediate
2 Risk Factors
37% cumulative risk of progression at 20 years (~2% per year). Consider haematology co-management.
Monitoring: SPEP and FLC every 3–6 months; regular haematology follow-up
High risk (3 risk factors): Approximately 58% cumulative risk of progression at 20 years (~3% per year). These patients require close haematology-led monitoring with SPEP, FLC, FBC, and renal function every 3–6 months. Discuss bone marrow biopsy at baseline.
Additional Baseline Assessments
- Suppression of uninvolved immunoglobulins (immune paresis): IgG <6 g/L, IgA <0.7 g/L, or IgM <0.4 g/L — associated with higher progression risk and increased infection susceptibility. Consider immunoglobulin replacement if recurrent infections.
- Urinary Bence Jones protein: significant light-chain excretion (>200 mg/24 h) may indicate occult light-chain myeloma or AL amyloidosis.
- Lactate dehydrogenase (LDH): elevated LDH may suggest high-grade transformation and warrants urgent assessment.
- Beta-2 microglobulin: not routinely required for MGUS but elevated levels are a poor prognostic marker if progression occurs.
- Albumin: low serum albumin may indicate nephrotic range proteinuria (AL amyloidosis) or systemic disease.
- Peripheral neuropathy assessment: IgM MGUS associated with anti-MAG antibody positivity may cause chronic demyelinating neuropathy requiring separate neurology assessment.
IgM MGUS — A Distinct Entity
IgM MGUS requires separate consideration. IgM MGUS does not typically progress to IgM myeloma but rather to Waldenström macroglobulinaemia (WM), a lymphoplasmacytic lymphoma. The Mayo Clinic IgM-MGUS model uses different thresholds: M-protein ≥15 g/L, abnormal FLC ratio, and bone marrow lymphoplasmacytic infiltration ≥10%. Additionally, MYD88 L265P mutation testing (available at reference laboratories) can help distinguish IgM MGUS from early WM. IgM MGUS patients with neuropathy should have anti-MAG antibodies assessed.
Light-Chain MGUS (LC-MGUS)
A small proportion of MGUS cases produce only free light chains without a detectable heavy-chain component on SPEP. These are termed light-chain MGUS (LC-MGUS) and account for approximately 15–20% of all MGUS cases. They carry a progression risk to light-chain myeloma or AL amyloidosis of approximately 0.3% per year. The FLC assay is the primary monitoring tool for LC-MGUS.
Distinguishing MGUS from Myeloma and Waldenström Macroglobulinaemia
The most critical task in managing an incidentally detected paraprotein is distinguishing MGUS from conditions that require active treatment. Three key entities must be considered: smouldering multiple myeloma (SMM), active multiple myeloma (MM), and Waldenström macroglobulinaemia (WM).
Diagnostic Criteria Comparison
| Criterion | MGUS | Smouldering Myeloma (SMM) | Active Myeloma (MM) |
|---|---|---|---|
| Serum M-protein | <30 g/L | ≥30 g/L | Any level with end-organ damage |
| Bone marrow plasma cells | <10% | 10–60% | ≥10% (or ≥60%) |
| CRAB features | Absent | Absent | Present |
| Myeloma-defining events (SLiM CRAB) | Absent | Absent | Present (SLiM or CRAB) |
| Treatment required | No — monitoring only | No — close monitoring or clinical trial | Yes — urgent initiation |
CRAB Criteria (Myeloma-Defining End-Organ Damage)
C
Hypercalcaemia
Corrected serum calcium >2.60 mmol/L. Symptoms: nausea, constipation, polyuria, confusion, cardiac arrhythmia.
R
Renal Impairment
Creatinine >177 µmol/L or eGFR <30 mL/min/1.73 m² attributable to the monoclonal protein (cast nephropathy, light-chain deposition disease).
A
Anaemia
Haemoglobin <100 g/L or >20 g/L below lower limit of normal. Caused by marrow infiltration or erythropoietin suppression.
B
Bone Lesions
One or more osteolytic lesions on skeletal survey, WBLD-CT, or PET-CT. Most commonly skull, spine, pelvis, ribs, and long bones.
SLiM Criteria (Additional Myeloma-Defining Events — IMWG 2014)
- S — Sixty percent or more bone marrow plasma cells
- Li — Light chain ratio involved/uninvolved FLC ≥100 with involved FLC ≥100 mg/L
- M — MRI-detected focal lesions: one or more focal lesions on MRI ≥5 mm
SLiM criteria indicate myeloma-defining events even in the absence of CRAB features and mandate treatment initiation (SMart treatment paradigm: treat before end-organ damage occurs).
Waldenström Macroglobulinaemia (WM)
WM is a lymphoplasmacytic lymphoma characterised by an IgM monoclonal protein and bone marrow infiltration by clonal lymphoplasmacytic cells. It is distinguished from IgM MGUS by:
- Bone marrow biopsy showing ≥10% clonal lymphoplasmacytic infiltration
- MYD88 L265P mutation (present in >90% of WM, also present in ~50–80% of IgM MGUS — its presence alone does not distinguish the two)
- Clinical features: hyperviscosity, lymphadenopathy, hepatosplenomegaly, B-symptoms
- IgM level >30 g/L associated with hyperviscosity risk (symptomatic hyperviscosity is a treatment indication)
Red Flags Demanding Urgent Haematology Referral
Refer urgently to haematology (within 1–2 weeks) if any of the following are present in a patient with a known or newly discovered paraprotein:
- Haemoglobin <100 g/L (new or worsening)
- Corrected calcium >2.60 mmol/L
- eGFR decline to <60 mL/min/1.73 m² not explained by other causes
- New bone pain, pathological fracture, or lytic lesions on imaging
- Unexplained weight loss (>5% body weight in 6 months)
- B-symptoms: drenching night sweats, fevers >38°C without infection
- New or worsening peripheral neuropathy (especially with IgM paraprotein)
- Rapid rise in M-protein (doubling within 6 months)
- Hyperviscosity symptoms: visual disturbance, mucosal bleeding, confusion (especially with high IgM)
- Hepatosplenomegaly or lymphadenopathy
In the absence of these red flags, patients with confirmed MGUS do not require emergency referral. However, all newly diagnosed MGUS patients should be reviewed by a haematologist at least once for baseline risk stratification and monitoring plan establishment.
Monitoring Plan
There is no pharmacological treatment for MGUS. Management is entirely based on periodic clinical and laboratory surveillance, with the aim of detecting progression to smouldering myeloma, active myeloma, WM, or another lymphoproliferative disorder at an early stage.
No treatment for MGUS. There is no evidence supporting prophylactic chemotherapy, bisphosphonates (in the absence of osteoporosis), or immunomodulatory drugs for MGUS. Clinical trials of early intervention in smouldering myeloma (e.g. CESAR, GEM-CESAR, Aquila) are ongoing and may change the paradigm for high-risk SMM, but MGUS management remains observation only.
Monitoring Frequency by Risk Category
| Risk Group | Year 1 | Years 1–5 | After 5 Years (if stable) | Lead Clinician |
|---|---|---|---|---|
| Low risk (0 factors) | SPEP + FLC at 6 months, then at 12 months | SPEP annually | May extend to every 2–3 years with haematology agreement | GP with haematology guidance |
| Low-intermediate (1 factor) | SPEP + FLC at 3–6 months, then at 12 months | SPEP + FLC every 6–12 months | Annual SPEP + FLC indefinitely | GP with haematology guidance |
| High-intermediate (2 factors) | SPEP + FLC at 2–3 months, then every 6 months | SPEP + FLC + FBC + Cr every 6 months | SPEP + FLC every 6–12 months indefinitely | Haematologist-led |
| High risk (3 factors) | SPEP + FLC + FBC + Cr + calcium every 3 months; bone marrow biopsy recommended | SPEP + FLC + FBC + Cr every 3–6 months | Continue every 6 months indefinitely | Haematologist-led |
| IgM MGUS | SPEP + IgM level + FLC at 3 months, then every 6 months | SPEP + IgM + FLC every 6 months | Annual monitoring if stable; closer if neuropathy present | Haematologist-led |
What to Monitor at Each Visit
- Clinical assessment: review for new bone pain, fatigue, recurrent infections, weight loss, night sweats, neuropathy symptoms, bleeding (mucosal or skin — may indicate hyperviscosity with IgM)
- SPEP with immunofixation: quantify M-protein and compare to previous values; a rising trend warrants closer follow-up
- Serum free light chain assay: monitor the FLC ratio and involved FLC level; progressive rise is concerning for clonal evolution
- Full blood count: assess for new cytopenias suggesting marrow infiltration
- Calcium and creatinine/eGFR: detect CRAB features early
- Quantitative immunoglobulins: assess for deepening immune paresis (may predispose to infection)
M-Protein Doubling Time — A Red Flag
If the M-protein doubles within 12 months (or the involved FLC doubles), this is an alarming feature suggesting possible transition to SMM or MM, even in the absence of CRAB criteria. Urgent haematology reassessment is indicated. Similarly, a new or rapidly rising IgM paraprotein may indicate transformation to WM and requires bone marrow biopsy.
When to Reassess Between Scheduled Visits
Patients should be counselled to present earlier than their next scheduled monitoring appointment if they develop any of the following between visits:
- New or worsening bone pain (particularly back, ribs, pelvis)
- Unexplained fatigue or pallor
- Unintentional weight loss
- Recurrent or unusual infections (pneumonia, herpes zoster, cellulitis)
- Unusual bleeding or bruising
- Visual disturbance or confusion (hyperviscosity — especially IgM)
- New or worsening numbness/tingling in extremities
- Nausea, constipation, or polyuria (hypercalcaemia)
- Foamy or frothy urine (proteinuria)
Patient Counselling and Resources
Effective counselling at the time of MGUS diagnosis is essential to balance appropriate vigilance against unnecessary anxiety. Key messages include:
- MGUS is not cancer — the vast majority of patients will never develop a malignancy
- It is the most common blood abnormality in older adults and is often described as a "precondition"
- No treatment is needed now; regular blood tests are the mainstay of care
- A small proportion (approximately 1 in 100 per year) may progress to conditions that need treatment — this is why monitoring is important
- Written information from the Leukaemia Foundation of Australia (leukaemia.org.au) or Blood Cancer Australia should be provided
- Patients should carry a summary of their MGUS diagnosis and monitoring plan
- Annual influenza vaccination and pneumococcal vaccination are recommended, especially if immune paresis is present
Investigations Summary & MBS Availability
The following table summarises the investigations required for MGUS workup and monitoring, their availability in Australia, and approximate Medicare schedule fees (subject to change — verify with current MBS schedule):
| Investigation | Purpose | Australian Availability | Frequency |
|---|---|---|---|
| SPEP + immunofixation | Quantify M-protein, confirm monoclonality, identify isotype | ✔ MBS — widely available | At diagnosis; then per risk category (see above) |
| Serum FLC (κ, λ, ratio) | Risk stratification; monitor clonal evolution | ✔ MBS — available at major labs | At diagnosis; then per risk category |
| Full blood count | Detect anaemia, cytopenias | ✔ MBS — universal | At each monitoring visit |
| Calcium (corrected) | Detect hypercalcaemia (CRAB) | ✔ MBS — universal | At each monitoring visit for intermediate/high risk |
| Creatinine / eGFR | Detect renal impairment (CRAB) | ✔ MBS — universal | At each monitoring visit |
| Quantitative immunoglobulins | Assess immune paresis | ✔ MBS — available | At diagnosis; annually or if infections occur |
| 24-hour urine protein / UPEP + immunofixation | Detect Bence Jones proteinuria | ✔ MBS — available | At diagnosis; repeat if progression suspected |
| WBLD-CT or skeletal survey | Detect lytic bone lesions | ✔ MBS — radiology referral required | At diagnosis; repeat if bone symptoms develop |
| Bone marrow biopsy | Quantify clonal plasma cells; distinguish MGUS from SMM/MM | ✔ MBS — haematologist-directed | If high risk, or if progression suspected |
| Whole-body MRI / PET-CT | Detect occult bone marrow disease; staging | Specialist — tertiary centre | When progression suspected and WBLD-CT negative |
| MYD88 L265P mutation | Distinguish IgM MGUS from WM | Reference laboratory — specialist ordered | IgM MGUS with rising M-protein or clinical features of WM |
| Anti-MAG antibodies | Evaluate IgM-associated neuropathy | ✔ MBS — reference laboratory | If IgM MGUS with peripheral neuropathy |
Special Populations
Pregnancy
MGUS in pregnancy is exceedingly rare. The vast majority of MGUS patients are over 50 years of age. If a paraprotein is detected incidentally during pregnancy, baseline workup and haematology referral should be performed but can be deferred to the postpartum period for non-urgent investigations (e.g. bone marrow biopsy, skeletal imaging with radiation).
Monitoring frequency — existing MGUS patients who become pregnant should maintain their usual monitoring schedule (SPEP, FLC). Radiation-based skeletal imaging should be avoided during pregnancy; MRI without gadolinium is the preferred modality if skeletal assessment is needed.
Placental transfer — IgG crosses the placenta; maternal IgG monoclonal protein may be detected in neonatal blood transiently. IgA and IgM do not cross the placenta efficiently.
Haematology co-management recommended if MGUS detected during pregnancy.
Paediatrics
MGUS in children is extremely rare (prevalence <0.1%). Monoclonal proteins detected in children are more likely to be transient and associated with infection (EBV, CMV, hepatitis), autoimmune disease, or post-transplant lymphoproliferative disorder (PTLD).
Consider alternative diagnoses first: immunodeficiency syndromes, autoimmune cytopenias, viral-associated monoclonal gammopathy. Repeat SPEP after 4–8 weeks — transient M-proteins often resolve.
If MGUS is confirmed, referral to paediatric haematology is mandatory. The Mayo Clinic risk-stratification model was derived in adults and has not been validated in children.
Paired paediatric and adult haematology input may be needed for adolescents.
Elderly (≥75 Years)
MGUS prevalence peaks in this age group (~8–10% of adults over 80 years). In very elderly patients, competing comorbidities and limited life expectancy may reduce the clinical significance of MGUS progression risk.
Monitoring intensity should be individualised. For patients with significant comorbidities and limited life expectancy, less frequent monitoring (annual or biennial SPEP) may be appropriate, particularly for low-risk MGUS.
Osteoporosis assessment is important in elderly MGUS patients. MGUS is associated with increased fracture risk independent of myeloma progression. Bone density assessment (DXA) and consideration of anti-resorptive therapy (denosumab or bisphosphonates) for osteoporosis management is recommended per Australian guidelines.
Immune paresis may contribute to infection susceptibility in the elderly. Immunoglobulin replacement therapy should be considered if recurrent infections occur with documented hypogammaglobulinaemia.
Balance vigilance with realistic patient-centred goals of care.
Renal Impairment
Baseline renal function must be assessed in all MGUS patients. If renal impairment is present at diagnosis, it is essential to determine whether it is attributable to the monoclonal protein (cast nephropathy, light-chain deposition disease, light-chain amyloidosis) or to other causes (diabetes, hypertension, age-related decline).
Monoclonal protein-related renal disease constitutes a myeloma-defining event (CRAB criterion) and requires urgent haematology referral. Consider nephrology referral for renal biopsy if light-chain amyloidosis or light-chain deposition disease is suspected.
If renal impairment is due to non-MGUS causes (e.g. diabetic nephropathy), monitoring for MGUS should continue per standard protocols, with awareness that renal function may fluctuate for reasons unrelated to the paraprotein.
A rising paraprotein in the setting of declining renal function warrants urgent reassessment.
Hepatic Impairment
Hepatic impairment does not directly affect MGUS monitoring as the investigations used (SPEP, FLC, FBC) are not hepatically metabolised. However, liver disease may cause secondary hypergammaglobulinaemia that can complicate SPEP interpretation.
Hepatitis C is associated with type II mixed cryoglobulinaemia and may cause a monoclonal gammopathy that is distinct from MGUS. If MGUS is detected in a patient with known hepatitis C, antiviral treatment may result in resolution of the paraprotein.
Consider hepatitis B and C serology at baseline MGUS workup, particularly in high-risk populations.
Immunocompromised
Post-transplant patients (solid organ and haematopoietic stem cell transplant recipients) have an increased prevalence of monoclonal gammopathy, which may be transient or associated with PTLD. Differentiation from classical MGUS requires specialist assessment.
HIV-associated monoclonal gammopathy is well-recognised and may be transient or associated with lymphoproliferative disease. MGUS in HIV-positive patients should be managed in collaboration with infectious disease and haematology teams.
Patients on immunosuppressive therapy for autoimmune conditions may develop transient monoclonal proteins. Repeat testing after a stable interval is recommended before committing to a diagnosis of MGUS.
Immune paresis management — if MGUS patients on immunosuppressive therapy develop recurrent infections with documented hypogammaglobulinaemia, immunoglobulin replacement should be considered (available via authority PBS).
Close haematology co-management is advised for immunocompromised MGUS patients.
MGUS-Associated Conditions
Although MGUS itself is asymptomatic, the monoclonal protein may be associated with specific clinical syndromes that require separate evaluation and management. These conditions are not progression to malignancy but rather immune-mediated consequences of the paraprotein.
MGUS-Associated Peripheral Neuropathy
IgM MGUS Neuropathy
- Most common MGUS-associated neuropathy
- Anti-MAG antibody positive in ~50% of cases
- Distal acquired demyelinating symmetric (DADS) phenotype
- Slowly progressive sensory > motor
- Nerve conduction studies: prolonged distal motor latencies
- Treatment: rituximab if severe/disabling; otherwise supportive care
IgG/IgA MGUS Neuropathy
- Less common than IgM-associated neuropathy
- May be axonal or demyelinating
- Mechanism less well understood
- Neurology referral recommended
- Consider CIDP (chronic inflammatory demyelinating polyradiculoneuropathy) overlap
- IVIg or corticosteroids may be trialled in CIDP-like cases
Other MGUS-Associated Conditions
| Condition | Association | Management |
|---|---|---|
| AL Amyloidosis | Light-chain MGUS may produce amyloidogenic light chains; low-level involvement possible | Screen with serum NT-proBNP, troponin, 24-hour urine protein, fat pad biopsy if suspected. Haematology referral. |
| POEMS Syndrome | Rare; almost always IgA or IgG λ light chain. Polyneuropathy, Organomegaly, Endocrinopathy, M-protein, Skin changes. | Specialist management at tertiary centre. Requires full systemic workup. |
| Scleromyxoedema | Associated with IgG λ MGUS. Generalised papular and sclerodermoid skin changes. | Dermatology and haematology co-management. |
| Cryoglobulinaemia | Type I cryoglobulinaemia is associated with IgM or IgG MGUS. May cause vasculitis, skin ulcers, Raynaud's phenomenon. | Avoid cold exposure; haematology referral for symptomatic disease. |
| MGUS-associated glomerulonephritis | Monoclonal immunoglobulin deposition disease (MIDD) — light-chain or heavy-light chain deposition in the kidney. | Nephrology and haematology co-management. Renal biopsy for diagnosis. |
Clinical pearl: MGUS-associated conditions (neuropathy, amyloidosis, POEMS) represent a separate indication for treatment of the underlying clone, distinct from progression to myeloma or WM. If a patient with MGUS develops one of these syndromes, the decision to treat should be made jointly by haematology and the relevant specialty (neurology, nephrology, etc.).
Aboriginal and Torres Strait Islander Health
Aboriginal and Torres Strait Islander Health Considerations for MGUS
📚 References
- 1. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564–569.
- 2. Kyle RA, Larson DR, Therneau TM, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378(3):241–249.
- 3. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548.
- 4. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749–757.
- 5. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215–224.
- 6. Bird J, Behrens J, Westin J, et al. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol. 2009;147(1):22–42.
- 7. Turesson I, Kovalchik AL, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years. Int J Cancer. 2014;135(5):1224–1230.
- 8. Morra E, Cesana C, Klersy C, et al. Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders. Leukemia. 2004;18(9):1512–1517.
- 9. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36(7):1703–1719.
- 10. Australian Institute of Health and Welfare. Cancer data in Australia. Canberra: AIHW; 2024. Available at: https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia.
- 11. Leukaemia Foundation of Australia. Understanding MGUS and smouldering myeloma. Brisbane: Leukaemia Foundation; 2023. Available at: https://www.leukaemia.org.au.
- 12. Castillo JJ. Individualizing treatment approach for Waldenström macroglobulinemia. Blood Adv. 2021;5(16):3274–3283.
- 13. NCCN Clinical Practice Guidelines in Oncology. Plasma Cell Neoplasms (including Multiple Myeloma). Version 2.2025. National Comprehensive Cancer Network; 2025.
- 14. Landgren O, Graubard BI, Kumar S, et al. Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12,372 individuals 10–49 years old: a population-based study from the National Health and Nutrition Examination Survey. Blood Cancer J. 2017;7(10):e618.
- 15. Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice (Red Book). 9th ed. Melbourne: RACGP; 2018.